The medical device firm raised its 2026 gross margin outlook to 58.5%-59.5% following a 38% year-over-year sales increase.
Beta Bionics reported $32 million in net sales for Q2 2026, a 38% year-over-year increase. Growth was driven by new patient starts and an expanding installed base of users accessing iLet supplies, according to management.
The company raised its 2026 gross margin outlook to 58.5%-59.5%, up from previous guidance. The Mint launch remains on track for the end of Q2 2027, with no changes to the timeline disclosed.
No immediate market reaction was detailed in the earnings call summary.